[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349956-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349956-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","beamion-pantumor-1-clinical-trial-protocol-rationale-and-design-phase-ii","Beamion PANTUMOR-1 - Clinical Trial Protocol - rationale and design - Phase II","","The protocol describes Beamion PANTUMOR-1, an open-label Phase II basket trial evaluating zongertinib monotherapy in previously treated patients with HER2-positive (overexpressed/amplified) or HER2-mutant solid tumors. Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor intended to reduce HER2-driven oncogenic activity while sparing wild-type EGFR to limit toxicities. The study enrolls patients into multiple tumor cohorts, treats with zongertinib 120 mg once daily, and assesses objective response as the primary endpoint. Secondary endpoints include duration of response, progression-free survival, disease control, treatment-emergent adverse events, and health-related quality of life, with recruitment ongoing across 13 countries.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/beamion-pantumor-1-clinical-trial-protocol-rationale-and-design-phase-ii/349956/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/beamion-pantumor-1-clinical-trial-protocol-rationale-and-design-phase-ii/349956.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the Beamion PANTUMOR-1 trial evaluating?","Question",{"text":63,"@type":64},"Beamion PANTUMOR-1 evaluates zongertinib monotherapy for efficacy and safety in previously treated patients with HER2-positive or HER2-mutant solid tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who can be enrolled, and how are patients grouped?",{"text":68,"@type":64},"Patients with HER2-positive tumors are assigned to eight cohorts, while patients with HER2-mutant tumors are assigned to five cohorts, covering tumor types such as urothelial, biliary tract, uterine, cervical, non-squamous lung, salivary gland, colorectal, breast, and gastroesophageal, plus tumor-agnostic options.",{"name":70,"@type":61,"acceptedAnswer":71},"How is zongertinib administered and what are the study endpoints?",{"text":72,"@type":64},"Patients receive zongertinib 120 mg orally once daily until progression, unacceptable toxicity, death, or withdrawal of consent. The primary endpoint is objective response based on central independent review using RECIST v1.1, with secondary endpoints including duration of response and progression-free survival, among others.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349956,1790189244,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 7, 795–803  \n[https://doi.org/10.1080/14796694.2026.2637740](https://doi.org/10.1080/14796694.2026.2637740)  \nCLINICAL TRIAL PROTOCOL  \nBeamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors  \nAlison M. Schram a, John J. Park b, Antoine Italianoc,d, Shigehisa Kitano e, Ye Guo f, Jin Li g,  \nPhilippe L. Bedard h, Cedric van Marcke i, Ryo Ko j, Lukas Lungerk, Daniel M. Klotzk, Jo Hussainl, Daniela Maierm, Damijan Erzen k, David Planchard n,o, Hans Prenen p, Timothy D. Clay q, Joon O. Park r,s, Hyung-Don Kim t, Alberto Hernando-Calvo u, Yuta Maruki v, Mariano Ponz-Sarvise w and Ecaterina Dumbrava x  \naDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; bMacquarie Medical School, Macquarie University, Sydney, NSW, Australia; cDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France; dDepartment of Medical Oncology, University of Bordeaux, Bordeaux, France; eDepartment of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; gMedical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; hDivision of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; iDepartment of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium; jDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; kGlobal Clinical Development ONCO, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany; lClinical Development Operations, Boehringer Ingelheim Ltd, Bracknell, Berkshire, UK; mGlobal Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; nDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France; oFaculty of Medicine, Paris-Saclay University, Paris, France; pMedical Oncology, University Hospital Antwerp, Edegem, Belgium; qMedical Oncology, St John of God Subiaco Hospital, Perth, WA, Australia; rDepartment of Medicine, Samsung Medical Center, Seoul, Korea; sDivision of Hematology-Oncology, Sungkyunkwan University School of Medicine, Seoul, Korea; tDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; uMedical Oncology, Vall d´Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; vDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan; wMedical Oncology, Cancer Center Clinica, Universidad de Navarra, Pamplona, Spain; xInvestigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \nABSTRACT  \nHuman epidermal growth factor receptor 2 (HER2, encoded by ERBB2) alterations are known oncogenicdrivers in many solid tumors. Zongertinib is a novel, oral, irreversible, HER2-selective tyrosine kinase inhibitor that spares wild-type epidermal growth factor receptor, thereby limiting associated toxicities. In a Phase Ia/Ib trial (NCT04886804), zongertinib demonstrated encouraging activity with a manageable safety profile in HER2-altered tumors (HER2 overexpression, amplification, or mutations) .  \nThe Phase II, open-label, Beamion PANTUMOR-1 basket trial (NCT06581432) is evaluating the efficacy and safety of zongertinib monotherapy in previously treated patients with HER2-positive (HER2-overexpressed/ amplified) or HER2-mutant solid tumors. Patients with HER2-positive tumors will be enrolled to one of eight cohorts: urothelial, biliary tract, uterine, cervical, non-squamous lung, salivary gland, colorectal or tumor agnostic. Patients with HER2-mutant tumors will be enrolled to one of five cohorts: urothelial, breast, gastroesophageal, bili","cbCaiuP2SlvWi91a","https://ap.wps.com/l/cbCaiuP2SlvWi91a","pdf",447875,"English","# ABSTRACT\n## Plain language summary","[{\"question\":\"What is the Beamion PANTUMOR-1 trial evaluating?\",\"answer\":\"Beamion PANTUMOR-1 evaluates zongertinib monotherapy for efficacy and safety in previously treated patients with HER2-positive or HER2-mutant solid tumors.\"},{\"question\":\"Who can be enrolled, and how are patients grouped?\",\"answer\":\"Patients with HER2-positive tumors are assigned to eight cohorts, while patients with HER2-mutant tumors are assigned to five cohorts, covering tumor types such as urothelial, biliary tract, uterine, cervical, non-squamous lung, salivary gland, colorectal, breast, and gastroesophageal, plus tumor-agnostic options.\"},{\"question\":\"How is zongertinib administered and what are the study endpoints?\",\"answer\":\"Patients receive zongertinib 120 mg orally once daily until progression, unacceptable toxicity, death, or withdrawal of consent. The primary endpoint is objective response based on central independent review using RECIST v1.1, with secondary endpoints including duration of response and progression-free survival, among others.\"}]","Beamion PANTUMOR-1 - Clinical Trial Protocol - rationale and design - Phase II | PDF",1790086449,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ee0191643b5f103c9cf63ac184b783.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b2eabebca754c23c05d84491e341679.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97f53e3d90acf0a62f75412ed3242159.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3b87c9c7ebc7643b8e7526adb588b72.webp",980,1276]